Results 151 to 160 of about 123,279 (307)

FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives

Haemophilia, EarlyView.
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita, Keiji Nogami, Chandrakala Shanmukhaiah   +2 more
wiley   +1 more source

Prothrombinase processivity is conferred by substrate allostery. [PDF]

EMBO J
Üstok FI, Faille A, Warren AJ, Huntington JA.   +3 more
europepmc   +1 more source

Rare Bleeding Disorders and Bleeding Disorder of Unknown Cause: Current Understanding and Recent Developments

Haemophilia, EarlyView.
ABSTRACT Rare bleeding disorders (RBDs) represent a diverse group of inherited conditions involving coagulation factors or platelets. These conditions, such as Glanzmann thrombasthenia (GT) or severe coagulation factor deficiencies, are uncommon. In contrast, bleeding disorder of unknown cause (BDUC) is a diagnosis of exclusion without an identifiable ...
Alessandro Casini, Robert Klamroth, Bauke Haisma, Dino Mehic, Saskia E. M. Schols   +4 more
wiley   +1 more source

Multi-Target Inhibition of F10/F2/PAR1 Through In Silico Drug Repurposing of Avodart and Naldemedine to Prevent Thrombotic-Induced Sudden Cardiac Arrest. [PDF]

Biomedicines
Al-Subaie AM, AbdulAzeez S.
europepmc   +1 more source

Seventh Åland Island Meeting on von Willebrand Disease

Haemophilia, EarlyView.
ABSTRACT Introduction The seventh Åland Island Meeting on von Willebrand Disease (VWD) was held on the Åland archipelago in Finland, from 26 to 28 September 2024. Aim The meeting brought together experts in the field of VWD from around the world to share the latest advances and knowledge in VWD.
Riitta Lassila, Ruben Bierings, Nathan T. Connell, Fernando F. Corrales‐Medina, Augusto B. Federici, Veronica H. Flood, Floor Heubel‐Moenen, Jill M. Johnsen, Geoffrey Kuppens, Davide Matino, Carolyn Millar, Ingmar Schoen, Anish Sharda, Robert F. Sidonio Jr, Alok Srivastava, Timea Szanto, Angela C. Weyand, Erik Berntorp   +17 more
wiley   +1 more source

Therapeutic targeting of blood-derived protein infiltration to modulate neuroinflammation in cerebellar ataxia. [PDF]

J Neuroinflammation
Park SM, Kim SS, Cho E, Lee GB, Lee JM, Kim DW, Kim JH, Kim JE, Choi GE, Lee HW, Suk K, Yoon JH, Kim S, Kim SR.   +13 more
europepmc   +1 more source

The Measurement of Prothrombin in Plasma [PDF]

Journal of Clinical Pathology, 1953
R, BIGGS, A S, DOUGLAS
openaire   +2 more sources

An Ex Vivo Pharmacodynamic Study of KN057, a Tissue Factor Pathway Inhibitor Neutralizing Antibody, in Plasma Samples From Patients With Haemophilia or VWD3

Haemophilia, EarlyView.
ABSTRACT Introduction Tissue factor pathway inhibitor (TFPI), a key regulator of tissue factor‐initiated coagulation through FXa‐dependent inhibition of the tissue factor‐FVIIa complex, has emerged as a promising target for restoring thrombin generation.
Mankai Ju, Feng Xue, Wei Sun, Fang Li, Ting Xu, Renchi Yang   +5 more
wiley   +1 more source

Role of prothrombin complex concentrate in the severe trauma patient

Frontiers in Medicine, 2022
Juan José Egea-Guerrero, Juan José Egea-Guerrero, Manuel Quintana-Diaz   +2 more
doaj   +1 more source

Prognostic model of patients with acute pancreatitis based on prothrombin time-international normalized ratio to albumin ratio: a single-center retrospective study. [PDF]

PeerJ
Zhou J, Jin Y, Zhang L, Cai Z, Liu J.
europepmc   +1 more source